3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Observational
2
Sponsor
Cancer Type
Lymphoid
3
Conditions
Lymphoma, Large B-Cell, Diffuse
10
Recurrence
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Burkitt Lymphoma
9
Lymphoma, Non-Hodgkin
3
Lymphoma, Follicular
3
Lymphoma, B-Cell
3
Neoplasm, Residual
2
Leukemia
2
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Biphenotypic, Acute
1
Interventions
Rituximab
295
Cyclophosphamide
240
Peripheral Blood Stem Cell Transplantation
114
fludarabine phosphate
110
Filgrastim
93
Etoposide
85
Radiotherapy
81
Lenalidomide
79
Vincristine
78
Prednisone
77
Mycophenolic Acid
66
Doxorubicin
61
Cyclosporine
59
Whole-Body Irradiation
58
Bendamustine Hydrochloride
58
Melphalan
57
Tacrolimus
53
Busulfan
51
fludarabine
50
Cytarabine
48
obinutuzumab
46
Methotrexate
45
Antilymphocyte Serum
43
Bortezomib
42
Methylprednisolone
37
Carmustine
37
sargramostim
36
ibritumomab tiuxetan
32
ibrutinib
30
Dexamethasone
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Lymphoma, Follicular
×
tisagenlecleucel
×
Clear all
NCT05888493
2026-04-17
LEDA
Novartis
Phase 3
Active not recruiting
109 enrolled
NCT03568461
2025-10-07
ELARA
Novartis
Phase 2
Completed
98 enrolled
9 charts
1 FDA
NCT03610724
2024-06-20
BIANCA
Novartis
Phase 2
Completed
34 enrolled
19 charts